Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Schwab Fundamental US Large Company Index ETF
FNDX
|
+$8.54B |
| 2 |
Vanguard Mortgage-Backed Securities ETF
VMBS
|
+$6.22B |
| 3 |
Schwab US Large- Cap ETF
SCHX
|
+$6.12B |
| 4 |
Schwab Fundamental US Small Company Index ETF
FNDA
|
+$5.39B |
| 5 |
Schwab 5-10 Year Corporate Bond ETF
SCHI
|
+$5.01B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Texas Instruments
TXN
|
+$367M |
| 2 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$335M |
| 3 |
Diageo
DEO
|
+$297M |
| 4 |
Medtronic
MDT
|
+$259M |
| 5 |
GE Aerospace
GE
|
+$222M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.36% |
| 2 | Financials | 10.66% |
| 3 | Healthcare | 9.68% |
| 4 | Consumer Discretionary | 8.35% |
| 5 | Industrials | 7.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3351
iShares MSCI USA Min Vol Factor ETF
USMV
$23.5B
| $321K | ﹤0.01% |
+3,820
| New | +$315K |
|
3352
Sanara MedTech
SMTI
$312M
| $320K | ﹤0.01% |
11,356
+1,024
| +10% | +$32.1K |
|
|
RGLS
3353
DELISTED
Regulus Therapeutics
RGLS
| $319K | ﹤0.01% |
+178,879
| New | +$415K |
|
3354
Greenwich LifeSciences
GLSI
$206M
| $319K | ﹤0.01% |
+18,454
| New | +$270K |
|
3355
Offerpad Solutions
OPAD
$19.6M
| $317K | ﹤0.01% |
7,162
+817
| +13% | +$50.7K |
|
3356
1stdibs.com
DIBS
$147M
| $316K | ﹤0.01% |
+70,326
| New | +$384K |
|
3357
ASP Isotopes
ASPI
$501M
| $316K | ﹤0.01% |
+103,119
| New | +$398K |
|
|
GTHX
3358
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $314K | ﹤0.01% |
137,921
+116,405
| +541% | +$445K |
|
3359
LiveOne
LVO
$61.6M
| $314K | ﹤0.01% |
20,002
+16,023
| +403% | +$283K |
|
3360
iShares MSCI Emerging Markets ETF
EEM
$28.6B
| $314K | ﹤0.01% |
+7,367
| New | +$309K |
|
|
TIXT
3361
DELISTED
TELUS International
TIXT
| $314K | ﹤0.01% |
+54,302
| New | +$379K |
|
3362
LiveWire
LVWR
$422M
| $311K | ﹤0.01% |
40,543
-4,048
| -9% | -$28.3K |
|
3363
iShares Core Universal USD Bond ETF
IUSB
$43B
| $310K | ﹤0.01% |
+6,866
| New | +$309K |
|
3364
Lifecore Biomedical
LFCR
$164M
| $310K | ﹤0.01% |
60,505
+50,078
| +480% | +$297K |
|
3365
Lifetime Brands
LCUT
$192M
| $301K | ﹤0.01% |
+35,087
| New | +$352K |
|
|
DNMR
3366
DELISTED
Danimer Scientific, Inc.
DNMR
| $301K | ﹤0.01% |
12,482
-4,934
| -28% | -$153K |
|
3367
Information Services Group
III
$197M
| $300K | ﹤0.01% |
102,126
+9,275
| +10% | +$31.2K |
|
3368
Geospace Technologies
GEOS
$93.1M
| $299K | ﹤0.01% |
+33,321
| New | +$375K |
|
3369
Aemetis
AMTX
$110M
| $299K | ﹤0.01% |
99,376
+85,177
| +600% | +$325K |
|
|
KWY
3370
Kingsway Corp
KWY
$256M
| $297K | ﹤0.01% |
36,073
+5,751
| +19% | +$47.7K |
|
3371
Global X US Preferred ETF
PFFD
$2.15B
| $294K | ﹤0.01% |
+14,930
| New | +$293K |
|
3372
Rekor Systems
REKR
$84.6M
| $294K | ﹤0.01% |
189,548
+167,541
| +761% | +$293K |
|
3373
Pioneer Bancorp
PBFS
$442M
| $293K | ﹤0.01% |
29,251
| – | – |
|
3374
Candel Therapeutics
CADL
$723M
| $290K | ﹤0.01% |
+46,777
| New | +$351K |
|
3375
PMV Pharmaceuticals
PMVP
$60.3M
| $289K | ﹤0.01% |
178,592
-87,332
| -33% | -$158K |
|
Similar funds
Charles Schwab's Q2 2024 Portfolio in Review
As of Q2 2024, Charles Schwab held 3,738 positions worth $525B, up 21% from $433B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Charles Schwab deployed $84.3B of net new capital in Q2 2024, opening 263 new positions and adding to 2,391 existing holdings. Its largest new stake was Schwab Fundamental US Small Company Index ETF: 195,294,508 shares worth $5.36B.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 23% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Texas Instruments, an estimated $367M trimmed.
- Charles Schwab's largest Q2 2024 buy was Schwab Fundamental US Small Company Index ETF: 195,294,508 shares worth $5.36B.
- Charles Schwab added most to Schwab Fundamental US Large Company Index ETF in Q2 2024, an estimated $8.54B increase.
- Charles Schwab's biggest Q2 2024 reduction was Texas Instruments, cutting an estimated $367M.
- Charles Schwab fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $335M.
- Charles Schwab's ten largest holdings make up 21% of its $525B portfolio in Q2 2024.
- Charles Schwab opened 263 new positions and closed 116 in Q2 2024.
- Charles Schwab's portfolio value rose 21% quarter-over-quarter to $525B.
Based on Charles Schwab's 13F filing for Q2 2024, filed 12 Aug 2024.